Trials / Completed
CompletedNCT03733561
A Study to Assess Pharmacokinetic Profiles of LY03003 and Neupro
A Randomized, Open-Label, Crossover Study to Evaluate the Pharmacokinetic Profiles of Rotigotine After a Single Dose of LY03003 (28 mg) Versus After a Week of Daily NEUPRO® Transdermal Patch (4 mg Every 24 Hours) in Healthy Volunteers
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 40 (actual)
- Sponsor
- Luye Pharma Group Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 45 Years
- Healthy volunteers
- Accepted
Summary
Phase 1, single center study to assess pharmacokinetic profiles of rotigotine after single dose of LY03003 and daily patch application of Neupro in Healthy Volunteers
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | LY03003 | LY03003 (rotigotine extended release microspheres for intramuscular \[IM\] injection) |
| DRUG | Neupro 4Mg/24Hr Transdermal Patch | neupro patch |
Timeline
- Start date
- 2018-11-09
- Primary completion
- 2018-12-23
- Completion
- 2018-12-23
- First posted
- 2018-11-07
- Last updated
- 2021-04-02
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03733561. Inclusion in this directory is not an endorsement.